SCHEMBL5455155

SCHEMBL5455155

O=C(Nc1ccc(O)nc1)c1c[c]ccc1O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.40
▸ KMT2A Q03164 5/20 0.40
▸ KDM4E B2RXH2 4/20 0.40
▸ HPGD P15428 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 4/20 0.39
▸ SORT1 Q99523 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ P4HTM Q9NXG6 2/20 0.37
▸ TP53 P04637 3/20 0.37
▸ HTT P42858 3/20 0.37
▸ HSD17B10 Q99714 2/20 0.37
▸ NPC1 O15118 3/20 0.37
▸ RAB9A P51151 3/20 0.37
▸ P2RX1 P51575 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ NFKB1 P19838 1/20 0.37
▸ NFKB2 Q00653 1/20 0.37
▸ RELA Q04206 1/20 0.37
▸ POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5457651 0.86 KCNQ3 (0.52) RAB9ASMN1; SMN2KCNQ3KCNQ2KCNE1
SCHEMBL5462336 0.83 RAB9A (0.53) MEN1KMT2AKDM4EALDH1A1LMNA
SCHEMBL5469832 0.80 LMNA (0.60) MEN1KMT2AKDM4EHPGDALDH1A1
SCHEMBL5468300 0.78 SNCA (0.56) MEN1KMT2ANPC1RAB9AP2RX1
SCHEMBL5462663 0.77 MEN1 (0.47) MEN1KMT2AKDM4EHPGDALDH1A1
SCHEMBL5464092 0.76 TOP1 (0.46) MEN1KMT2AKDM4EHPGDLMNA
SCHEMBL5462330 0.75 PNLIP (0.62) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL5463888 0.74 PTGS1 (0.56) MEN1KMT2AKDM4ELMNAMAPT
SCHEMBL14363272 0.74 PLAU (0.58) MEN1KMT2ALMNAP4HTMTP53
SCHEMBL5463771 0.73 RAB9A (0.51) MEN1KMT2AKDM4EHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 — — US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 MEN1 2892/4885KMT2A 2948/4885KDM4E 3789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback